Skip to main content
What do we know about gender equity in academic rheumatology?

Dr. Nicola Dalbeth (@NicolaDalbeth) shares her thoughts.

Dr. John Cush RheumNow

3 years 4 months ago
What do we know about gender equity in academic rheumatology? Dr. Nicola Dalbeth (@NicolaDalbeth) shares her thoughts. https://t.co/ha4UvqEygk https://t.co/tmGhFUW09t
For patients with uncontrolled gout, estimated glomerular filtration rate (eGFR) remained stable with combination pegloticase (Krystexxa) and methotrexate treatment, researchers reported.
RheumThoughts: The Benefits of Networking

Dr. Rachel Tate ( @uptoTate ) discusses the importance and benefits of networ

Dr. John Cush RheumNow

3 years 4 months ago
RheumThoughts: The Benefits of Networking Dr. Rachel Tate ( @uptoTate ) discusses the importance and benefits of networking. RheumThoughts are opinion pieces from healthcare professionals in the RheumNow network. https://t.co/Ug3N4F4CGI https://t.co/vpXSsrlCcd
6 specialties saw a pay drop in 2023 - #6 on the list was Rheumatology at -3% (based on Medscape survey of 10,011 physic

Dr. John Cush RheumNow

3 years 4 months ago
6 specialties saw a pay drop in 2023 - #6 on the list was Rheumatology at -3% (based on Medscape survey of 10,011 physicians 1022-1/23. Biggest drop was Ophthalmology -7% (then EM -6%, PM&R -5%, Nephrology -5%, Allergy -5%, RHEUM -3%) https://t.co/9P7ujh2Tw0 https://t.co/8DaGUsrROY
Women physician leaders have made significant contributions in various fields, such as business leaders as CEOs and board members, public health through national and international advocacy efforts, and the non-profit sector. "To Lead or Not To Lead" - that is the question.
Study of 9558 pts found significant associations betw migraine and CTS Median nerve decompression (OR, 1.3) & multip

Dr. John Cush RheumNow

3 years 4 months ago
Study of 9558 pts found significant associations betw migraine and CTS Median nerve decompression (OR, 1.3) & multiple nerve decompressions (OR, 1.7). Also assoc w/ migraine: psych dz, RA, CVS, hypothyroid, HTN, COPD https://t.co/cIdkACHGwB https://t.co/VO3VqujzSQ
Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64)

Dr. John Cush RheumNow

3 years 4 months ago
Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64), with 41% of pts switched from RTX to CT-P10. Both Rx had Comparable Gr 2 infuxion Rxs, infection #s & hypogammaglobulinemia (p > 0.05) https://t.co/RNxt7Xn7MJ https://t.co/u3yJNQQIMC
Doctor’s Contracts: Pitfalls and Traps

Dr. Dao ( @KDAO2011) spoke with Andrea Liberatore, JD, to explain what to loo

Dr. John Cush RheumNow

3 years 4 months ago
Doctor’s Contracts: Pitfalls and Traps Dr. Dao ( @KDAO2011) spoke with Andrea Liberatore, JD, to explain what to look for in a contract. https://t.co/w44pWWyhpo https://t.co/fy5vlve4IQ
Retrospective study on prescribing by male vs female RHEUMs, found that women (in private practice, >10 yrs) were les

Dr. John Cush RheumNow

3 years 4 months ago
Retrospective study on prescribing by male vs female RHEUMs, found that women (in private practice, >10 yrs) were less likely to be High steroid prescribers. RA Pts more likely to Rx steroids = male sex, >prior biologics, opioid use, w/ comorbidities & freq infx https://t.co/eO3yJRCfOR
Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).
The European Commission has approved upadacitinib (Rinvoq) for the Treatment of Moderately to Severely Active Crohn's Di

Dr. John Cush RheumNow

3 years 4 months ago
The European Commission has approved upadacitinib (Rinvoq) for the Treatment of Moderately to Severely Active Crohn's Disease https://t.co/Clzca7jU5b https://t.co/nNFGe5fF25
12 mos. serial study of 71 pts with gout found 42% with at least 1 gout flare (median=2) over 12 mos. US eval. showed "F

Dr. John Cush RheumNow

3 years 4 months ago
12 mos. serial study of 71 pts with gout found 42% with at least 1 gout flare (median=2) over 12 mos. US eval. showed "Flare" pts had signif more MSU deposits (6.7 vs 2.9) & power Doppler (3.73 vs 0.82)vs controls. By US- were 17-29% more likely to flare. https://t.co/icDyNEsCa6 https://t.co/86pgBzG9MC
Lillys IL-23 inhibitor (Mirakizumab) has suffered a minor setback receiving a "complete response letter" from the FDA re

Dr. John Cush RheumNow

3 years 4 months ago
Lillys IL-23 inhibitor (Mirakizumab) has suffered a minor setback receiving a "complete response letter" from the FDA regarding MIRA application (BLA) for use in ulcerative colitis. The CRL hold up is related to the manufacturing issues (not data/safety) https://t.co/Xs93pFNFAp https://t.co/vlVP8qiqGr
Pain and Opioid Updates

The CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use o

Dr. John Cush RheumNow

3 years 4 months ago
Pain and Opioid Updates The CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids. https://t.co/jjN9zvX7rV https://t.co/kY3kX1S8vq
Retrospective study of 147 THA and TKA pts w/ acute/chronic complaint - 39 pts Dx w/ prosthetic joint infection (PJI).

Dr. John Cush RheumNow

3 years 4 months ago
Retrospective study of 147 THA and TKA pts w/ acute/chronic complaint - 39 pts Dx w/ prosthetic joint infection (PJI). Absolute numbers of neutrophils (PMNs) best predicted PJI (THA > 3,600 PMN/µl; TKA >2,000 PMN/µl (sensitivity 97%; specificity 93.5%) https://t.co/pxKcsTT6tn https://t.co/IQZ0DSUxwc
×